Related Experiment Videos
Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left
Insights
Oral hydralazine effectively reduces afterload in patients with coronary artery disease and left ventricular dysfunction. This treatment improves cardiac output and reduces pulmonary capillary wedge pressure at rest and during exercise.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) and left ventricular dysfunction (LVD) significantly impair cardiac function.
- Afterload reduction is a key therapeutic strategy to improve hemodynamics in these patients.
Purpose of the Study:
- To evaluate the hemodynamic effects of oral hydralazine for afterload reduction.
- To assess the impact of hydralazine on cardiac function at rest and during exercise in CAD patients with LVD.
Main Methods:
- A study involving 12 patients with CAD and LVD.
- Hemodynamic parameters were measured at rest and during exercise before and after 48 hours of oral hydralazine (50-75 mg every 6 hours).
- Radionuclide angiocardiography assessed left ventricular volumes and ejection fraction.
Main Results:
- Hydralazine significantly increased cardiac output and reduced pulmonary capillary wedge pressure and systemic vascular resistance at rest and during exercise.
- Oxygen consumption and heart rate remained unchanged.
- Left ventricular volumes and ejection fraction showed no significant changes.
- Clinical improvement was observed in 7 out of 12 patients during follow-up.
Conclusions:
- Oral hydralazine provides sustained hemodynamic benefits at rest and during exertion in patients with CAD and LVD.
- Chronic afterload reduction with hydralazine may enhance cardiac reserve and alleviate symptoms like dyspnea and angina.
Abstract:
To determine the hemodynamic effects of afterload reduction at rest and during upright exercise in patients with coronary artery disease and left ventricular dysfunction, 12 patients were studied before and after taking 50-75 mg of oral hydralazine every 6 hours for 48 hours. Oxygen consumption and heart rate were unchanged from control both at rest and during two work loads on a bicycle ergometer. Cardiac output was significantly increased at rest and during both workloads. The arteriovenous oxygen difference was significantly reduced at rest and during exercise. Pulmonary capillary wedge pressure was also significantly lower at rest and during exercise. Systemic vascular resistance was reduced at rest, and exercise-induced vasodilation was augmented by the administration of hydralazine. Left ventricular end-diastolic volume and ejection fraction assessed by radionuclide angiocardiography were not significantly changed at rest or during exercise after hydralazine. Seven of the 12 patients have maintained clinical improvement during a follow-up of 6-12 months. Hemodynamic improvement provided by oral hydralazine at rest is maintained during moderate exertion in patients with coronary artery disease and left ventricular dysfunction. In selected patients, chronic afterload reduction with oral hydralazine may result in increased cardiac reserve, decreased pulmonary congestion or decreased myocardial oxygen demands, thereby improving or abolishing resting or exertional dyspnea or angina.